Table 1.

Trials comparing allo-HSCT with chemotherapy in acute leukemia

References	Diagnosis	Risk Stratification	CIR	DFS	OS
Lv et al. [11]	Adult Int-AML HID-HSCT vs. CT	Int-AML	11.7% vs. 49.0% p < 0.0001	74.3% vs. 47.3%; p = 0.0004	80.8% vs. 53.5%; p = 0.0001
Zhu et al. [15]	Adult t(8;21)AML-CR1 HSCT vs. CT	High risk: RUNX1-RUNX1 reduction < 3 log units loss of MMR within 6 months	HR 22.1% vs 78.9%	61.7% vs 19.6%	71.6% vs 26.7%
Duan et al. [16]	Adult inv(16)AML-CR1 HSCT vs. CT	CBFB-MYH11/ABL levels > 0.1% at any time after two consolidation cycles	not report	84.6% vs. 31.4%, p < 0.001	76.0% vs. 71.0%; p = 0.283
Deng et al. [21]	CEBPAbi + AML CR1	sustained positive MRD after two consolidations	0% vs. 52.8%; p = 0.006	88.9% vs. 47.2%; p = 0.027	88.9% vs. 58.6%;p = 0.484
Huang et al. [23]	NPM1 + FLT3 +  CT vs. HSCT	Int or fav-AML	not report	HR 0.138 p < 0.001	HR 0.173 p = 0.001
Chen et al. [106]	NPM-FLT3 +  CT vs. HSCT	FLT3-ITD mutant ratio (high and low) FLT3-ITD mutant length (long and short)	FLT3 + HR 0.237 p < 0.001; regardless of Ratio/Length	FL3 + HR 0.330 p < 0.001; regardless of Ratio/Length	not report
Wang et al. [59]	Ph + ALL HSCT vs. CT + TKIs	white blood cell counts ≥ 30 × 109/L at diagnosis; less than 3 log reduction of BCR-ABL levels after two consolidation cycles	1 risk factor: 23.6 vs. 36.9%, p = 0.017; 2 risk factors: 37.5 vs. 100.0%, p < 0.001	1 risk factor:62.4 vs. 43.8%, p = 0.048; 2 risk factors:56.2 vs. 0%, p < 0.001	1 risk factor:76.1% vs. 47.7%, p = 0.037; 2 risk factors:51.4% vs. 6.3%, p = 0.001
Lv et al. [32]	Adult Ph-ALL HID-HSCT vs. CT	Standard risk-ALL	12.8% vs 46.7%, p = 0.0017	80.9% vs 51.1%, p = 0.0116	91.2% vs 75.7%, p = 0.0408

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CT, Chemotherapy; HSCT, hematopoietic stem cell transplantation; HID, haploidentical donor; HR, high risk; Int, intermediate risk; DFS, disease-free survival; TKIs, tyrosine kinase inhibitors; Sig, Statistical Significance